Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (381-390 of 445) with videos related to

Pageof 45
Sort By:
Oncogene|January 30, 2022
SMARCA4 biology in alveolar rhabdomyosarcomaNarendra Bharathy, Megan M Cleary, Jin-Ah Kim, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649Y Y Janjigian, K Shitara, J A Ajani, et al.
The Lancet. Oncology|July 3, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyTanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 29, 2025
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon ResponseJinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic CancerHarshabad Singh, Joanne Xiu, Kevin S Kapner, et al.
Journal of Hepatology|March 20, 2024
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinomaLixia Xu, Ying Zhang, Zhilong Lin, et al.
Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Advances in Nutrition (Bethesda, Md.)|July 22, 2025
Co-creating and Mapping an Exclusive Breastfeeding Framework among Latino Populations in the United States: An Integrated Framework Adaptation Process and Scoping ReviewArmando Peña, Zoe Barnsfather, Alison M Miller, et al.
Pageof 45

Showing results (381-390 of 445) with videos related to

Sort By:
Pageof 45
Oncogene|January 30, 2022
SMARCA4 biology in alveolar rhabdomyosarcomaNarendra Bharathy, Megan M Cleary, Jin-Ah Kim, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649Y Y Janjigian, K Shitara, J A Ajani, et al.
The Lancet. Oncology|July 3, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyTanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 29, 2025
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon ResponseJinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic CancerHarshabad Singh, Joanne Xiu, Kevin S Kapner, et al.
Journal of Hepatology|March 20, 2024
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinomaLixia Xu, Ying Zhang, Zhilong Lin, et al.
Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Advances in Nutrition (Bethesda, Md.)|July 22, 2025
Co-creating and Mapping an Exclusive Breastfeeding Framework among Latino Populations in the United States: An Integrated Framework Adaptation Process and Scoping ReviewArmando Peña, Zoe Barnsfather, Alison M Miller, et al.
Pageof 45